Trials
3 active
14 in total · 5 in the EU
What this is
- How it works
- Blocks a kinase, an enzyme that passes "grow" or "activate" signals inside cells. Most are cancer drugs.-tinib: tyrosine kinase inhibitors WHO name stem
- Main trialPhase 3
- “The objective is to compare the efficacy and safety of masitinib in combination with riluzole versus matched placebo in combination with riluzole for the treatment of Amyotrophic Lateral Sclerosis (ALS).”In the company’s words, NCT03127267 on ClinicalTrials.gov
- Other names
- AB1010
Other drugs for Amyotrophic Lateral Sclerosis
Coming up3
- Dec 2027Phase 3 trial completes · ClinicalTrials.gov
- 31 Dec 2028Phase 3 trial completes · ClinicalTrials.gov
- Dec 2028Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials14
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | Dec 2027 | Efficacy and Safety of Masitinib Versus Placebo in the Treatment of ALS Patients | |
| Phase 3Not yet recruiting | 31 Dec 2028 | Efficacy and Safety of Masitinib in Combination With SoC Versus Placebo in the Treatment of ALS Patients | |
| Phase 3Not yet recruiting | Dec 2028 | Masitinib in Patients With Mild Alzheimer's Disease | |
| Phase 3Terminated | Jul 2018 | Masitinib in First Line Treatment of Gastro-Intestinal Stromal Tumor (GIST) | |
| Phase 3Completed | Nov 2019 | Masitinib in Treatment of Patients With Severe Persistent Asthma Treated With Oral Corticosteroids | |
| Phase 3Completed | 15 Dec 2020 | Masitinib Plus Docetaxel in Metastatic Castration-resistant Prostate Cancer | |
| Phase 3Completed | Dec 2020 | Masitinib in Patients With Mild to Moderate Alzheimer's Disease | |
| Phase 3Unknown | Dec 2024 | Masitinib in Severe Indolent or Smoldering Systemic Mastocytosis Unresponsive to Optimal Symptomatic Treatment | |
| Phase 3Suspended | Dec 2028 | Masitinib in the Treatment of Patients With Primary Progressive or Non-active Secondary Progressive Multiple Sclerosis | |
| Phase 2/3Completed | 5 Dec 2016 | Masitinib in Combination With Riluzole for the Treatment of Patients Suffering From Amyotrophic Lateral Sclerosis (ALS) | |
| Phase 2Unknown | Dec 2023 | Masitinib Combined With Isoquercetin and Best Supportive Care in Hospitalized Patients With Moderate and Severe COVID-19 | |
| Phase 2Unknown | Dec 2023 | Masitinib in Patients With Symptomatic Mild to Moderate COVID-19 | |
| Phase 2Unknown | 31 Dec 2024 | Masitinib for the Treatment of Severe Mast Cell Activation Syndrome | |
| Phase 3Ended | not given | A 96-Week, Prospective, Multicenter, Randomised, Double-Blind, Placebo-Controlled, Phase 3 Study to Compare Efficacy and Safety of Masitinib Dose Titration to 4.5 mg/kg/day versus Placebo in the Treatment of Patients with Primary Progressive or Secondary Progressive Multiple Sclerosis Without Relapse |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026